Nanoparticles for co-delivery of paclitaxel and curcumin to overcome chemoresistance against breast cancer

Lin, Xiangping; Wang, Qun; Du, Shuang; Guan, Yucheng; Qiu, Jinmei; Chen, Xiao‐Jia; Yuan, Dongsheng; Chen, Tongkai

doi:10.1016/j.jddst.2022.104050

Cited by 12 publications

(10 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Probably, under the assay conditions (pH 7.4), only the initial desorption of CUR deposited outside the NPs occurred. Alternatively, the equilibrium shift toward equalizing the osmotic pressure inside and outside the dialysis bag may also have affected CUR release at pH 7.4 . Such events can be supported by an interesting work performed by Mujokoro et al ., whose research group observed that the PLGA polymeric matrix took approx.…”

Section: Resultsmentioning

confidence: 87%

“…Alternatively, the equilibrium shift toward equalizing the osmotic pressure inside and outside the dialysis bag may also have affected CUR release at pH 7.4. 29 Such events can be supported by an interesting work performed by Mujokoro et al, 27 whose research group observed that the PLGA polymeric matrix took approx. 20 days to collapse after incubation at pH 7.4 and 37 °C, thus delaying significantly the drug release.…”

Section: Curcumin Release From Plga Nanoparticles Undermentioning

confidence: 83%

“…Thus, the nanoformulation based on PLGA NPs to CUR delivery has proven to increase its absorption in the organism and protect it from degrading agents, in addition to allowing the design of versatile DDS for different applications. In this sense, formulations comprising CUR-loaded PLGA NPs have recently promoted: ( i ) increase in bone regeneration in implanted areas in type-2 diabetic mice; ( ii ) decrease in the Aβ plaques aggregation, which is directly associated to inflammatory processes of the Alzheimer’s disease; ( iii ) anti-COVID-19 activities; ( iv ) anticancer activities against some of the most dangerous types of tumors, such as liver, brain, and chemoresistant breast cancer; − ( v ) anti-atherosclerotic activity; and ( vi ) reversal of corticosteroid resistance in smokers …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Selection and Control of Process Conditions Enable the Preparation of Curcumin-Loaded Poly(lactic-co-glycolic acid) Nanoparticles of Superior Performance

Feltrin

D'Angelo

Guarnieri

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Curcumin (CUR) is one natural bioactive compound acknowledged for diverse therapeutic activities, but its use is hindered by its poor bioavailability, fast metabolism, and susceptibility to pH variations and light exposure. Thus, the encapsulation in poly(lactic-co-glycolic acid), or PLGA, has been successfully used to protect and enhance CUR absorption in the organism, making CUR-loaded PLGA nanoparticles (NPs) promising drug delivery systems. However, few studies have focused beyond CUR bioavailability, on the environmental variables involved in the encapsulation process, and whether they could help obtain NPs of superior performance. Our study evaluated pH (3.0 or 7.0), temperature (15 or 35 °C), light exposure, and inert atmosphere (N2) incidence in the encapsulation of CUR. The best outcome was at pH 3.0, 15 °C, without light incidence, and without N2 usage. This best nanoformulation showed NP size, zeta potential, and encapsulation efficiency (EE) of 297 nm, −21 mV, and 72%, respectively. Moreover, the CUR in vitro release at pH values 5.5 and 7.4 suggested different potential applications for these NPs, one of which was demonstrated by the effective inhibition of multiple bacteria (i.e., Gram-negative, Gram-positive, and multi-resistant) in the minimal inhibition concentration assay. Besides, statistical analyses confirmed a significant impact of temperature on the NP size; in addition, temperature, light, and N2 affected the EE of CUR. Thus, the selection and control of process variables resulted in higher CUR encapsulation and customizable outcomes, ultimately enabling more economical processes and providing future scale-up guidelines.

show abstract

Section: Resultsmentioning

confidence: 87%

Section: Curcumin Release From Plga Nanoparticles Undermentioning

confidence: 83%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Selection and Control of Process Conditions Enable the Preparation of Curcumin-Loaded Poly(lactic-co-glycolic acid) Nanoparticles of Superior Performance

Feltrin

D'Angelo

Guarnieri

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…The optimized PPN PCL-NPs displayed a biphasic release profile, with an initial burst release of 47.82 ± 3.92% within the initial 6 h interval, succeeded by a prolonged release extending over a duration of 48 h. This initial burst release was ascribed to drug molecules either adsorbed onto the surface or encapsulated within the outer core of the PPN-PCL-NPs. This phenomenon may also be ascribed to enhanced surface area due to the small PS of nanocarriers . Following the rapid initial release, PPN-PCL-NPs demonstrated a controlled release profile.…”

Section: Resultsmentioning

confidence: 99%

“…This phenomenon may also be ascribed to enhanced surface area due to the small PS of nanocarriers. 52 Following the rapid initial release, PPN-PCL-NPs demonstrated a controlled release profile. The extended release can be attributed to the process of drug diffusion originating from the inner core of the polymer matrix.…”

Section: Stability Studymentioning

confidence: 99%

Development of Statistically Optimized Piperine-Loaded Polymeric Nanoparticles for Breast Cancer: In Vitro Evaluation and Cell Culture Studies

Gilani,

Bin-Jumah,

Fatima

2023

ACS Omega

View full text Add to dashboard Cite

Piperine (PPN) is a natural alkaloid derived from black pepper (Piper nigrum L.) and has garnered substantial attention for its potential in breast cancer therapy due to its diverse pharmacological properties. However, its highly lipophilic characteristics and poor dissolution in biological fluids limit its clinical application. Therefore, to overcome this limitation, we formulate and evaluate PPN-encapsulated polycaprolactone (PCL) nanoparticles (PPN-PCL-NPs). The nanoparticles were prepared by a single-step nanoprecipitation method and further optimized by a formulation design approach. The influence of selected independent variables PCL (X 1), poloxamer 188 (P-188; X 2), and stirring speed (SS; X 3) were investigated on the particle size (PS), polydispersity index (PDI), and % encapsulation efficiency (EE). The selected optimized nanoparticles were further assessed for stability, in vitro release, and in vitro antibreast cancer activity in the MCF-7 cancer cell line. The PS, PDI, zeta potential, and % EE of the optimized PPN-PCL-NPs were observed to be 107.61 ± 5.28 nm, 0.136 ± 0.011, −20.42 ± 1.82 mV, and 79.53 ± 5.22%, respectively. The developed PPN-PCL-NPs were stable under different temperature conditions with insignificant changes in their pharmaceutical attributes. The optimized PPN-PCL-NPs showed a burst release for the first 6 h and later showed sustained release for 48 h. The PPN-PCL-NPs exhibit exceptional cytotoxic effects in MCF-7 breast tumor cells in comparison with the native PPN. Thus, the formulation of PPN-loaded PCL-NPs can be a promising approach for better therapeutic efficacy against breast cancer.

show abstract

Assembly of nanostructured lipid carriers loaded gefitinib and simvastatin as hybrid therapy for metastatic breast cancer: Codelivery and repurposing approach

Sherif

Shahba

Nasr

et al. 2023

Drug Development Research

View full text Add to dashboard Cite

Breast cancer represents a life‐threatening problem globally. The major challenge in the clinical setting is the management of cancer resistance and metastasis. Hybrid therapy can affect several cellular targets involved in carcinogenesis with a lessening of adverse effects. Therefore, the current study aims to assemble, and optimize a hybrid of gefitinib (GFT) and simvastatin (SIM)‐loaded nanostructured lipid carrier (GFT/SIM‐NLC) to combat metastatic and drug‐resistant breast cancer. GFT/SIM‐NLC cargos were prepared using design of experiments to investigate the impact of poloxamer‐188 and fatty acids concentrations on the physicochemical and pharmaceutical behavior properties of NLC. Additionally, the biosafety of the prepared GFT/SIM‐NLC was studied using a fresh blood sample. Afterward, the optimized formulation was subjected to an MTT assay to study the cytotoxic activity of GFT/SIM‐NLC compared to free GFT/SIM using an MCF‐7 cell line as a surrogate model for breast cancer. The present results revealed that the particle size of the prepared NLC ranged from (209 to 410 nm) with a negative zeta potential value ranging from (−17.2 to −23.9 mV). Moreover, the optimized GFT/SIM‐NLC formulation showed favorable physicochemical properties and promising lymphatic delivery cargos. A biosafety study indicates that the prepared NLC has a gentle effect on erythrocyte hemolysis. Cytotoxicity studies revealed that GFT/SIM‐NLC enhanced the killing of the MCF‐7 cell line compared to free GFT/SIM. This study concluded that the hybrid therapy of GFT/SIM‐NLC is a potential approach to combat metastatic and drug‐resistant breast cancer.

show abstract

Nanoparticles for co-delivery of paclitaxel and curcumin to overcome chemoresistance against breast cancer

Cited by 12 publications

References 47 publications

Selection and Control of Process Conditions Enable the Preparation of Curcumin-Loaded Poly(lactic-co-glycolic acid) Nanoparticles of Superior Performance

Selection and Control of Process Conditions Enable the Preparation of Curcumin-Loaded Poly(lactic-co-glycolic acid) Nanoparticles of Superior Performance

Development of Statistically Optimized Piperine-Loaded Polymeric Nanoparticles for Breast Cancer: In Vitro Evaluation and Cell Culture Studies

Assembly of nanostructured lipid carriers loaded gefitinib and simvastatin as hybrid therapy for metastatic breast cancer: Codelivery and repurposing approach

Contact Info

Product

Resources

About